REGN vs TSLX · P/E 14, rev $4.29B vs P/E 14, $1.57B cap
Regeneron Pharmaceuticals Inc (REGN) versus Sixth Street Specialty Lending Inc (TSLX) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Sixth Street Specialty Lending Inc (TSLX) is a asset management company listed on NYSE.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
TSLX does not have a complete income-statement cache yet.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. TSLX currently screens at market cap $1.57B and trailing P/E 14.3.
Not investment advice. Open the REGN and TSLX stock pages for the full models.
Not investment advice.